VERA
NASDAQVera Therapeutics Inc.
Website
News25/Ratings12
News · 26 weeks77-62%
2025-10-262026-04-19
Mix4490d
- Insider21(48%)
- Other12(27%)
- SEC Filings7(16%)
- Leadership3(7%)
- Analyst1(2%)
Latest news
25 items- INSIDERSEC Form 4 filed by Fordyce Marshall4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- PRVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on April 8, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 258,200 shares of Class A common stock and restricted stock units (RSUs) underlying 131,925 shares of Class A common stock to eighty-nine (89) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
- SECSEC Form DEFA14A filed by Vera Therapeutics Inc.DEFA14A - Vera Therapeutics, Inc. (0001831828) (Filer)
- SECSEC Form DEF 14A filed by Vera Therapeutics Inc.DEF 14A - Vera Therapeutics, Inc. (0001831828) (Filer)
- SECSEC Form SCHEDULE 13G filed by Vera Therapeutics Inc.SCHEDULE 13G - Vera Therapeutics, Inc. (0001831828) (Subject)
- PRVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on March 23, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 56,850 shares of Class A common stock and restricted stock units (RSUs) underlying 42,403 shares of Class A common stock to Jane Wright-Mitchell, Vera's new Chief Legal Officer under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employee's employment in accordance with Nasdaq List
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Vera Therapeutics Inc.SCHEDULE 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)
- INSIDERSEC Form 4 filed by Wright-Mitchell Jane4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- INSIDERSEC Form 3 filed by new insider Wright-Mitchell Jane3 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- PRVera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal OfficerBRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jane Wright-Mitchell, Pharm.D., J.D., as Chief Legal Officer, effective immediately. "Jane has worked with Vera Therapeutics previously as a strategic legal consultant and brings a depth and breadth of experience in supporting companies through regulatory approvals, commercialization, and intellectual property management," said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. "As we near the potential launch of
- INSIDERSVP, FINANCE, CHIEF ACCT OFFCR Young Joseph R exercised 10,000 shares at a strike of $3.94, increasing direct ownership by 15% to 75,754 units (SEC Form 4)4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- ANALYSTVera Therapeutics upgraded by Wolfe Research with a new price targetWolfe Research upgraded Vera Therapeutics from Peer Perform to Outperform and set a new price target of $88.00
- SECVera Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Vera Therapeutics, Inc. (0001831828) (Filer)
- INSIDERSEC Form 4 filed by Director Hite Christopher4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hite Christopher3 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- PRVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on March 3, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 46,000 shares of Class A common stock and restricted stock units (RSUs) underlying 25,875 shares of Class A common stock to six (6) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock
- PRVera Therapeutics Appoints Christopher Hite to Board of DirectorsBRISBANE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christopher Hite, an accomplished executive with decades of corporate and financial strategy leadership experience in the biopharmaceutical sector, to Vera Therapeutics' Board of Directors. "It is a pleasure to welcome Chris to our Board of Directors at this exciting juncture in Vera Therapeutics' trajectory as we near the potential launch of our first-in-class dual BAFF/APRIL inhibitor for patients with IgA nephropathy," sa
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Vera Therapeutics Inc.SCHEDULE 13D/A - Vera Therapeutics, Inc. (0001831828) (Subject)
- SECSEC Form 10-K filed by Vera Therapeutics Inc.10-K - Vera Therapeutics, Inc. (0001831828) (Filer)
- SECVera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Vera Therapeutics, Inc. (0001831828) (Filer)
- PRVera Therapeutics Provides Business Update and Reports Full Year 2025 Financial ResultsPositive Phase 3 data from ORIGIN 3 study of atacicept in IgA nephropathy (IgAN) presented at American Society of Nephrology (ASN) Kidney Week and published in the New England Journal of MedicineU.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for atacicept with Prescription Drug User Fee Act (PDUFA) date of July 7, 2026; potential commercial launch of atacicept expected in mid-2026Strong balance sheet bolstered by equity and debt financings in 2025 expected to be sufficient to fund company beyond atacicept approval and U.S. commercial launch BRISBANE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a l
- INSIDERChief Medical Officer Brenner Robert sold $90,307 worth of shares (2,151 units at $41.98), decreasing direct ownership by 4% to 50,947 units (SEC Form 4)4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- INSIDERSVP, FINANCE, CHIEF ACCT OFFCR Young Joseph R sold $130,864 worth of shares (3,117 units at $41.98), decreasing direct ownership by 5% to 64,722 units (SEC Form 4)4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Grant Sean sold $207,778 worth of shares (4,949 units at $41.98), decreasing direct ownership by 4% to 114,181 units (SEC Form 4)4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- INSIDERPRESIDENT AND CEO Fordyce Marshall sold $710,578 worth of shares (16,925 units at $41.98), decreasing direct ownership by 6% to 257,163 units (SEC Form 4)4 - Vera Therapeutics, Inc. (0001831828) (Issuer)